- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02164643
Longitudinal Study of Brain Amyloid imaGing in MEMENTO (MEMENTOAmyGing)
Study Overview
Status
Intervention / Treatment
Detailed Description
Alzheimer's disease (AD) is the most common cause of dementia in the elderly, affecting approximately 7.3 million people in Europe. AD is a clinicopathologic entity for which the definitive diagnosis requires both the presence of the clinical signs of dementia and pathological evidence of amyloid plaque in the brain (obtained at autopsy).
Currently, diagnosis of AD at early stage of the disease is hampered by the lack of noninvasive and validated biomarkers of the underlying pathology. On one hand, it is suggested that between 10% and 20% of patients currently diagnosed with AD, based on clinical evidence solely, lack AD pathology at autopsy, and on the other hand community physicians may not diagnose AD in 33% of patients with mild signs and symptoms. Thus, there is a need for validated diagnostic biomarker that could help clinicians separate patients who do not have AD from those who have pathological signs and should be referred for further evaluation and care management. Furthermore, little is known on the prognosis value for dementia conversion of current biomarkers of AD pathology at a preclinical or presymptomatic stage.
Recently, 18F-labeled positron emission tomography (PET) imaging agents have been developed that bind with high affinity to the amyloid-β (Aβ) peptide fibrils that constitute amyloid plaques, and thus, have potential value as an imaging biomarkers for amyloid deposits in subjects with cognitive impairment or isolated cognitive complaints.
The principal objective of this ancillary study is to investigate the prospective association between PET amyloid load, measured twice two years apart, through either Florbetapir (18F) or Flutemetamol (18F) radioligands, and dementia incidence over up to 5 years of follow-up in a sample of individuals presenting with a spectrum of cognitive profiles ranging from isolated cognitive complaints to cognitive deficits without dementia.
The secondary objectives are the following:
- To assess the association between change in amyloid load and clinical evolution of participants (both functional and cognitive)
- To estimate the prevalence of new research criteria for preclinical Alzheimer's disease
- To investigate long-term outcome of preclinical Alzheimer's disease according to NIA-AA criteria
- To assess the determinants of change in amyloid load over two years
- To study the interrelationships between biomarkers
- To assess the added value of amyloid binding agent (Florbetapir (18F) and Flutemetamol (18F)) in combination with other biomarkers (neuropsychological, genetics, plasma, serum, CSF, structural neuroimaging, 18F-FDG-PET) to predict clinical dementia onset
- To assess the diagnostic accuracy of amyloid agent Florbetapir (18F) and Flutemetamol (18F) to differentiate AD from other types of dementia (differential diagnosis)
- To study the link between amyloid binding agent and survivalstudy design
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Angers, France
- CHU d'Angers
-
Besancon, France
- CHU de Besancon
-
Bobigny, France
- AP-HP - Avicenne
-
Bordeaux, France, 33000
- CHU de Bordeaux - Pellegrin
-
Bordeaux, France
- CHU de Bordeaux - Hôpital Xavier-Arnozan
-
Brest, France
- CHU de Brest
-
Clermont-ferrand, France
- CHU de Clermont-Ferrand
-
Dijon, France
- CHU de Dijon
-
Grenoble, France
- Chu de Grenoble
-
Lille, France
- CHU de Lille
-
Lyon, France
- Hospices Civils de Lyon
-
Marseille, France
- AP-HM
-
Montpellier, France
- CHU de Montpellier
-
Nancy, France
- Chu de Nancy
-
Nice, France
- CHU de Nice
-
Paris, France
- AP-HP - hôpital Lariboisière
-
Paris, France
- AP-HP - Hôpital BROCA
-
Paris, France
- AP-HP La Pitié-Salpétrière
-
Poitiers, France
- Chu de Poitiers
-
Rouen, France
- CHU de Rouen
-
Saint-etienne, France
- CHU de Saint-Etienne - Hôpital de la charité
-
Saint-etienne, France
- CHU de Saint-Etienne - Hôpital Nord
-
Strasbourg, France
- CHU de Strasbourg
-
Toulouse, France
- CHU de Toulouse
-
Toulouse, France
- CHU de Toulouse - Hôpital Purpan
-
Tours, France
- CHU de Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- To be included in MEMENTO
- To have signed a specific MEMENTO-AmyGing informed consent form, prior to any amyloid PET procedures
- To have had or agreed to have 18F-FDG PET scan in MEMENTO
- To tolerate the (18F) PET scan procedures, in the opinion of the clinical site investigator
- Clinical Dementia Rating scale <0.5 and not demented
Exclusion Criteria:
- To have a current clinically significant psychiatric condition that neurologists/geriatricians feel would preclude the ability to have a research PET scan
- To be pregnant or breastfeading women
- To have Hypersensitivity to the tracer or to the excipient listed in the summary of the product carateristics (florbetapir Amyvid®) or the Investigator's Brochure (flutemetamol)
- To have a relevant history of severe drug allergy or hypersensitivity (relevant severe drug allergies should be determined by the clinical site investigator or co-clinical site investigator). If a subject has a history of severe drug allergies, it may be dangerous for them to participate in a study with a novel compound
- To have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, γ-secretase or γ-secretase inhibitor) unless it can be documented that the subject received only placebo during the course of the trial
- To receive any investigational medications, or have participated in a trial with investigational medications within the last 30 days
- To have participated less than 1 year ago in a biomedical research with injection of one of the amyloid radioligand or to be enrolled in an ongoing biomedical research including amyloid PET scan
- To have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Florbetapir (18F)
|
|
Experimental: Flutemetamol (18F)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression to clinical dementia stage according to standardized classifications (DSM-IV and NINCDS-ADRDA) as described in the MEMENTO protocol.
Time Frame: 24 months from baseline
|
24 months from baseline
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Longitudinal evolution of amyloid load measured through either Florbetapir (18F) or Flutemetamol (18F)
Time Frame: 24 months from baseline
|
24 months from baseline
|
Speed of cognitive decline based on change in cognitive performances
Time Frame: 24 months from baseline
|
24 months from baseline
|
Longitudinal evolution of biomarkers measured from blood, CSF, structural neuroimaging (MRI) and glucose metabolism molecular neuroimaging (18F-FDG PET).
Time Frame: 24 months from baseline
|
24 months from baseline
|
Mortality
Time Frame: 24 months from baseline
|
24 months from baseline
|
Loss of autonomy based on functional activity assessment
Time Frame: 24 months from baseline
|
24 months from baseline
|
Institutionalization
Time Frame: 24 months from baseline
|
24 months from baseline
|
Cardiovascular event (Stroke and Coronary events)
Time Frame: 24 months from baseline
|
24 months from baseline
|
Quality of life
Time Frame: 24 months from baseline
|
24 months from baseline
|
Prodromal AD (Pre-symptomatic dementia)
Time Frame: 24 months from the baseline
|
24 months from the baseline
|
Etiology of dementia, when converted
Time Frame: 24 months from the baseline
|
24 months from the baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Genevieve CHENE, Prof, CIC-EC7 - ISPED - CHU de Bodeaux
- Study Chair: Geneviève CHENE, Prof, CIC-EC7 - ISPED - CHU de Bordeaux
- Study Director: Carole DUFOUIL, Director, CIC-EC7 - ISPED - CHU de Bordeaux
- Study Director: Florence PASQUIER, Prof, Head of Lille Memory Clinic, CHRU Lille
- Study Director: Marie-Odile HABERT, Prof, Head of Molecular Imaging Work package for the Center for Image Acquisition and Processing - CHU Pitié-Salpêtrière, AP-HP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2010/47 A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease (AD) and Related Disorders
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
-
University Hospital, BordeauxFondation Plan AlzheimerCompletedAlzheimer's Disease (AD) and Related DisordersFrance
-
CHU de ReimsCompletedAlzheimer's Disease (AD) and Related DisordersFrance
-
Chong Kun Dang PharmaceuticalCompletedAlzheimer's Disease (AD)Korea, Republic of
-
Sheba Medical CenterUnknownCognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia RiskAlzheimer's Disease (AD)Israel
-
Molecular NeuroImagingRoche Pharma AG; Institute for Neurodegenerative DisordersCompletedAlzheimer's Disease (AD)United States
-
University Hospital, ToursRecruiting
-
Mayo ClinicCompletedAlzheimer's Disease (AD)United States
-
AbbVieRecruitingAlzheimer's Disease (AD)United States, Japan, New Zealand, Australia, Spain, Germany, United Kingdom
Clinical Trials on Florbetapir (18F)
-
Avid RadiopharmaceuticalsWithdrawnAlzheimer's DiseaseJapan
-
Avid RadiopharmaceuticalsEli Lilly and CompanyCompleted
-
Avid RadiopharmaceuticalsCompleted
-
Avid RadiopharmaceuticalsEli Lilly and CompanyCompletedMild Cognitive Impairment | Alzheimer's DiseaseJapan
-
InvicroCompletedAlzheimer Disease | Healthy Volunteers | Progressive Supranuclear PalsyUnited States
-
InvicroRecruiting
-
Avid RadiopharmaceuticalsCompletedProgressive Cognitive DeclineUnited States
-
Avid RadiopharmaceuticalsNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedParkinson's DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer's Disease